Dana Investment Advisors Inc. Sells 54,542 Shares of Bristol Myers Squibb Company $BMY

Dana Investment Advisors Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 37.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 90,612 shares of the biopharmaceutical company’s stock after selling 54,542 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Bristol Myers Squibb were worth $4,087,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Gateway Investment Advisers LLC grew its position in shares of Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after buying an additional 10,284 shares during the period. CWA Asset Management Group LLC boosted its stake in Bristol Myers Squibb by 25.9% during the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC grew its holdings in Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after purchasing an additional 11,690 shares during the period. Stephens Inc. AR increased its stake in Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after purchasing an additional 32,476 shares in the last quarter. Finally, Railway Pension Investments Ltd raised its holdings in shares of Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after purchasing an additional 40,300 shares during the period. Institutional investors own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted the NDA for iberdomide in relapsed/refractory multiple myeloma and granted Priority Review and Breakthrough Therapy designation — a fast regulatory path that could add a new oral therapy to BMY’s oncology franchise and materially boost future revenue if approved. FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review
• Positive Sentiment: Positive top-line registrational Phase 2 results for luspatercept in adults with alpha‑thalassemia — successful data supports a potential label expansion (new indication) and adds to the company’s near-term pipeline value. Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $75 price target, highlighting pipeline potential and supporting higher analyst sentiment and buy-side interest. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential
• Neutral Sentiment: Market commentary and valuation pieces are re‑rating BMY as investors digest the clinical/regulatory wins — these articles analyze upside and valuation multiples but don’t add immediate cash-flow changes. Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates
• Neutral Sentiment: BMY will present at the TD Cowen Health Care Conference — an opportunity for management to update investors on pipeline timelines and commercial plans; typically a catalyst for guidance clarity but not an immediate earnings event. Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Analysts and coverage notes continue to flag a looming patent/exclusivity cliff for some key products — a structural risk that could pressure revenue beyond the near-term pipeline gains. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

Wall Street Analyst Weigh In

Several analysts have recently commented on BMY shares. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research report on Tuesday. They issued a “sector perform” rating and a $60.00 target price for the company. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research report on Wednesday, December 3rd. HSBC reiterated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $60.71.

Bristol Myers Squibb Stock Up 0.6%

Shares of NYSE:BMY opened at $61.61 on Wednesday. The business’s 50 day moving average is $56.50 and its 200 day moving average is $50.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock has a market cap of $125.48 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.